Treatment of alcohol dependence in patients with co-morbid major depressive disorder - Predictors for the outcomes with memantine and escitalopram medication

Substance Abuse: Treatment, Prevention, and Policy

Volumn 3, Issue , 2008, Pages

  Muhonen, Leea H ^a,d   Lahti, Jari ^b   Sinclair, David ^a   Lönnqvist, Jouko ^a,b,c   Alho, Hannu ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Helsinki City Health Center   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; MEMANTINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ALCOHOLISM; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MEMANTINE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 54349088773     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-3-20     Document Type: Article

References (57)

1. Kessler RC Berglund P Demler O Jin R Merikangas KR Walters EE Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 2005, 62(6):593-602. 15939837
2. Kessler RC Crum RM Warner LA Nelson CB Schulenberg J Anthony JC Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey Arch Gen Psychiatry 1997, 54(4):313-321. 9107147
3. Pettinati HM Antidepressant treatment of co-occurring depression and alcohol dependence Biol Psychiatry 2004, 56(10):785-792. 15556124
4. Rounsaville BJ Dolinsky ZS Babor TF Meyer RE Psychopathology as a predictor of treatment outcome in alcoholics Arch Gen Psychiatry 1987, 44(6):505-513. 3579499
5. Pettinati HM Volpicelli JR Luck G Kranzler HR Rukstalis MR Cnaan A Double-blind clinical trial of sertraline treatment for alcohol dependence J Clin Psychopharmacol 2001, 21(2):143-153. 11270910
6. Willinger U Lenzinger E Hornik K Fischer G Schonbeck G Aschauer HN Meszaros K Anxiety as a predictor of relapse in detoxified alcohol-dependent patients Alcohol Alcohol 2002, 37(6):609-612. 12414556
7. Cloninger CR A systematic method for clinical description and classification of personality variants. A proposal Arch Gen Psychiatry 1987, 44(6):573-588. 3579504
8. Verheul R Brink van den W Geerlings P A three-pathway psychobiological model of craving for alcohol Alcohol Alcohol 1999, 34(2):197-222. 10344781
9. Spanagel R Recent animal models of alcoholism Alcohol Res Health 2000, 24(2):124-131. 11199279
10. Virkkunen M Linnoila M Serotonin in early onset, male alcoholics with violent behaviour Ann Med 1990, 22(5):327-331. 2291840
11. Naranjo CA Knoke DM The role of selective serotonin reuptake inhibitors in reducing alcohol consumption J Clin Psychiatry 2001, 62(Suppl 20):18-25. 11584871
12. Johnson BA Role of the serotonergic system in the neurobiology of alcoholism: Implications for treatment CNS Drugs 2004, 18(15):1105-1118. 15581381
13. Kiefer F Helwig H Tarnaske T Otte C Jahn H Wiedemann K Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome Eur Addict Res 2005, 11(2):83-91. 15785069
14. Verheul R Lehert P Geerlings PJ Koeter MW Brink van den W Predictors of acamprosate efficacy: Results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients Psychopharmacology (Berl) 2005, 178(2-3):167-173. 15322728
15. Cornelius JR Bukstein O Salloum I Clark D Alcohol and psychiatric comorbidity Recent Dev Alcohol 2003, 16:361-374. 12638646
16. Cornelius JR Salloum IM Thase ME Haskett RF Daley DC Jones-Barlock A Upsher C Perel JM Fluoxetine versus placebo in depressed alcoholic cocaine abusers Psychopharmacol Bull 1998, 34(1):117-121. 9564208
17. Amit Z Sutherland EA Gill K Ogren SO Zimeldine: A review of its effects on ethanol consumption Neurosci Biobehav Rev 1984, 8(1):35-54. 6328388
18. Naranjo CA Sellers EM Lawrin MO Modulation of ethanol intake by serotonin uptake inhibitors J Clin Psychiatry 1986, 47(Suppl)16-22. 3007443
19. Naranjo CA Bremner KE Evaluation of the effects of serotonin uptake inhibitors in alcoholics: A review Novel Pharmcological Interventions for Alcoholism New York: Springer-Verlag Naranjo CA, Sellers EM 1992:105-117.
20. Thase ME Managing depressive and anxiety disorders with escitalopram Expert Opin Pharmacother 2006, 7(4):429-440. 16503815
21. Tiihonen J Ryynanen OP Kauhanen J Hakola HP Salaspuro M Citalopram in the treatment of alcoholism: A double-blind placebo-controlled study Pharmacopsychiatry 1996, 29(1):27-29. 8852531
22. Kranzler HR Burleson JA Brown J Babor TF Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics Alcohol Clin Exp Res 1996, 20(9):1534-1541. 8986200
23. Chick J Aschauer H Hornik K Efficacy of fluvoxamine in preventing relapse in alcohol dependence: A one-year, double-blind, placebo-controlled multicentre study with analysis by typology Drug Alcohol Depend 2004, 74(1):61-70. 15072808
24. Cloninger CR Sigvardsson S Gilligan SB von Knorring AL Reich T Bohman M Genetic heterogeneity and the classification of alcoholism Adv Alcohol Subst Abuse 1988, 7(3-4):3-16. 3066194
25. Babor TF Hofmann M DelBoca FK Hesselbrock V Meyer RE Dolinsky ZS Rounsaville B Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity Arch Gen Psychiatry 1992, 49(8):599-608. 1637250
26. Cornelius JR Salloum IM Ehler JG Jarrett PJ Cornelius MD Perel JM Thase ME Black A Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial Arch Gen Psychiatry 1997, 54(8):700-705. 9283504
27. Owens MJ Knight DL Nemeroff CB Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine Biol Psychiatry 2001, 50(5):345-350. 11543737
28. Montgomery SA Baldwin DS Blier P Fineberg NA Kasper S Lader M Lam RW Lepine JP Moller HJ Nutt DJ Which antidepressants have demonstrated superior efficacy? A review of the evidence Int Clin Psychopharmacol 2007, 22(6):323-329. 17917550
29. De Witte P Littleton J Parot P Koob G Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action CNS Drugs 2005, 19(6):517-537. 15963001
30. Lesch OM Riegler A Gutierrez K Hertling I Ramskogler K Semler B Zoghlami A Benda N Walter H The European acamprosate trials: Conclusions for research and therapy J Biomed Sci 2001, 8(1):89-95. 11173981
31. Soyka M Roesner S New pharmacological approaches for the treatment of alcoholism Expert Opin Pharmacother 2006, 7(17):2341-2353. 17109610
32. Pettinati HM Rabinowitz AR Choosing the right medication for the treatment of alcoholism Curr Psychiatry Rep 2006, 8(5):383-388. 16968619
33. Gortelmeyer R Erbler H Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study Arzneimittelforschung 1992, 42(7):904-913. 1418054
34. Maler JM Esselmann H Wiltfang J Kunz N Lewczuk P Reulbach U Bleich S Ruther E Kornhuber J Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons Brain Res 2005, 1052(2):156-162. 16009352
35. Holter SM Danysz W Spanagel R Evidence for alcohol anti-craving properties of memantine Eur J Pharmacol 1996, 314(3):R1-2. 8957265
36. Bachteler D Economidou D Danysz W Ciccocioppo R Spanagel R The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat Neuropsychopharmacology 2005, 30(6):1104-1110. 15668725
37. Bachteler D Spanagel R Glutamatergic compounds: A perspective Drugs for Relapse Prevention for Alcoholism Basel: Birkhäuser Verlag Spanagel R, Mann KF 2005:205-216.
38. Piasecki J Koros E Dyr W Kostowski W Danysz W Bienkowski P Ethanol-reinforced behaviour in the rat: Effects of uncompetitive NMDA receptor antagonist, memantine Eur J Pharmacol 1998, 354(2-3):135-143. 9754913
39. Escher T Call SB Blaha CD Mittleman G Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice Psychopharmacology (Berl) 2006, 187(4):424-434. 16835770
40. Bisaga A Evans SM Acute effects of memantine in combination with alcohol in moderate drinkers Psychopharmacology (Berl) 2004, 172(1):16-24. 14530901
41. Krupitsky EM Neznanova O Masalov D Burakov AM Didenko T Romanova T Tsoy M Bespalov A Slavina TY Grinenko AA Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients Am J Psychiatry 2007, 164(3):519-523. 17329479
42. Evans SM Levin FR Brooks DJ Garawi F A pilot double-blind treatment trial of memantine for alcohol dependence Alcohol Clin Exp Res 2007, 31(5):775-782. 17378918
43. Zarate CA Jr Singh JB Quiroz JA De Jesus G Denicoff KK Luckenbaugh DA Manji HK Charney DS A double-blind, placebo-controlled study of memantine in the treatment of major depression Am J Psychiatry 2006, 163(1):153-155. 16390905
44. Muhonen LH Lonnqvist J Juva K Alho H Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence J Clin Psychiatry 2008, 69(3):392-399. 18348597
45. Anton RF Obsessive-compulsive aspects of craving: Development of the Obsessive Compulsive Drinking Scale Addiction 2000, 95(Suppl 2):S211-217. 11002915
46. Saunders JB Aasland OG Babor TF de la Fuente JR Grant M Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II Addiction 1993, 88(6):791-804. 8329970
47. Aalto M Tuunanen M Sillanaukee P Seppa K Effectiveness of structured questionnaires for screening heavy drinking in middle-aged women Alcohol Clin Exp Res 2006, 30(11):1884-1888. 17067353
48. Gual A Segura L Contel M Heather N Colom J AUDIT-3 and AUDIT-4: effectiveness of two short forms of the alcohol use disorders identification test Alcohol Alcohol 2002, 37(6):591-596. 12414553
49. Poikolainen K Karkkainen P Diary gives more accurate information about alcohol consumption than questionnaire Drug Alcohol Depend 1983, 11(2):209-216. 6861618
50. Goldstein BI Diamantouros A Schaffer A Naranjo CA Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders Drugs 2006, 66(9):1229-1237. 16827599
51. Berglund M Thelander S Salaspuro M Franck J Andreasson S Ojehagen A Treatment of alcohol abuse: An evidence-based review Alcohol Clin Exp Res 2003, 27(10):1645-1656. 14574236
52. Nunes EV Levin FR Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis JAMA 2004, 291(15):1887-1896. 15100209
53. Moak DH Anton RF Latham PK Voronin KE Waid RL Durazo-Arvizu R Sertraline and cognitive behavioral therapy for depressed alcoholics: Results of a placebo-controlled trial J Clin Psychopharmacol 2003, 23(6):553-562. 14624185
54. Dawson DA Grant BF Stinson FS Chou PS Huang B Ruan WJ Recovery from DSM-IV alcohol dependence: United States, 2001-2002 Addiction 2005, 100(3):281-292. 15733237
55. Vaillant GE A 60-year follow-up of alcoholic men Addiction 2003, 98(8):1043-1051. 12873238
56. Heinala P Alho H Kiianmaa K Lonnqvist J Kuoppasalmi K Sinclair JD Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial J Clin Psychopharmacol 2001, 21(3):287-292. 11386491
57. Muhonen LH Lönnqvist J Lahti J Alho H Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence Psychiatry Res 2008.